Correlogic Systems Obtains CE Mark for OvaCheck® | SYS-CON MEDIA

media: June 9th: "Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians...."

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536.....

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

CONCLUSIONS: BI 2536 showed limited antitumour activity according to the design of this trial in five different tumour types. Derivatives of BI 2536 with a more favourable pharmacological profile are currently explored further in prospective studies.

Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committe

media: Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency

Invitation to European-based patient groups/patients to participate in an online survey on patient information - PatientView alerts and updates

Current Controlled Trials - Database of Clinical Trials - Europe

Note: this is a database of European clinical trials - the database has been around for many years  

Search for trials: Trials uniquely identified by an ISRCTN Search across multiple registers (including the NHS in England and US ClinicalTrials.gov)

European Medicines Agency (EMA): the Agency takes a further step in its interaction with patients and consumers | A global voice for patients

REFLECTION PAPER ON THE FURTHER INVOLVEMENT OF PATIENTS AND CONSUMERS IN THE AGENCY’S ACTIVITIES

Wait Times For Medical Care: How The US Actually Measures Up - Better Health

Note: ACOR ovarian cancer members - the report will be in the archives - Commonwealth Fund

Europe: (including e-health Health Executive Summit: Visions, Strategies, Best Practices

Calls to Make Europe the Global Leader for Medical Devices